Evidence map›Paper›PMID 33915751›Full record

ArticleLife (Basel, Switzerland)2021

Transcription Factor Activity Inference in Systemic Lupus Erythematosus.

Raul Lopez-Dominguez, Daniel Toro-Dominguez, Jordi Martorell-Marugan, Adrian Garcia-Moreno, Christian H Holland, Julio Saez-Rodriguez, Daniel Goldman, Michelle A Petri, Marta E Alarcon-Riquelme, Pedro Carmona-Saez

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 5 countries.

Raul Lopez-DominguezCentre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, 18016 Granada, Spain.ORCID 0000-0001-8634-117X
Daniel Toro-DominguezCentre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, 18016 Granada, Spain.
Jordi Martorell-MaruganCentre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, 18016 Granada, Spain.ORCID 0000-0002-5186-0735
Adrian Garcia-MorenoCentre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, 18016 Granada, Spain.ORCID 0000-0002-5715-4962
Christian H HollandFaculty of Medicine, Institute of Computational Biomedicine, Heidelberg University, 69120 Heidelberg, Germany.ORCID 0000-0002-3060-5786
Julio Saez-RodriguezFaculty of Medicine, Institute of Computational Biomedicine, Heidelberg University, 69120 Heidelberg, Germany.ORCID 0000-0002-8552-8976
Daniel GoldmanDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0001-5003-3503
Michelle A PetriDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Marta E Alarcon-RiquelmeCentre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, 18016 Granada, Spain.ORCID 0000-0002-7632-4154
Pedro Carmona-SaezCentre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, 18016 Granada, Spain.
Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESHeidelberg University · DEJohns Hopkins University · USEcorys (Netherlands) · NLKarolinska Institutet · SEUniversidad de Granada · ES

Funding

Hopkins Lupus CohortR01AR069572 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 2016 to 2020
$3.4M
Consejería de Salud, Junta de Andalucía PI-0173-2017NIAMS NIH HHS R01 AR069572
6 · The paper itself

Abstract

backgroundSystemic Lupus Erythematosus (SLE) is a systemic autoimmune disease with diverse clinical manifestations. Although most of the SLE-associated loci are located in regulatory regions, there is a lack of global information about transcription factor (TFs) activities, the mode of regulation of the TFs, or the cell or sample-specific regulatory circuits. The aim of this work is to decipher TFs implicated in SLE.

methodsIn order to decipher regulatory mechanisms in SLE, we have inferred TF activities from transcriptomic data for almost all human TFs, defined clusters of SLE patients based on the estimated TF activities and analyzed the differential activity patterns among SLE and healthy samples in two different cohorts. The Transcription Factor activity matrix was used to stratify SLE patients and define sets of TFs with statistically significant differential activity among the disease and control samples.

resultsTF activities were able to identify two main subgroups of patients characterized by distinct neutrophil-to-lymphocyte ratio (NLR), with consistent patterns in two independent datasets-one from pediatric patients and other from adults. Furthermore, after contrasting all subgroups of patients and controls, we obtained a significant and robust list of 14 TFs implicated in the dysregulation of SLE by different mechanisms and pathways. Among them, well-known regulators of SLE, such as STAT or IRF, were found, but others suggest new pathways that might have important roles in SLE.

conclusionsThese results provide a foundation to comprehend the regulatory mechanism underlying SLE and the established regulatory factors behind SLE heterogeneity that could be potential therapeutic targets.

Indexed as

clustering analysisdisease classificationsystemic lupus erythematosustranscription factor activity inference

Identifiers

PMID33915751
PMCPMC8065841
OpenAlexW3146039784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.